Abstract
Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing I.DI from human plasma were developed on the basis of the antibodies preparation. The sorbents caled “Immunoliposorber PcAb” and “Immunoliposorber McAb” are currently undergoing clinical trials in the USSR Cardiology Research Center, Acad. of Med. Sciences.